AWARD A CONTRACT FOR RADX TECH - CERES TO DEVELOP A WASTEWATER COVID-19 SURVEILLANCE FRAMEWORK DRIVEN BY PUBLIC HEALTH AUTHORITIES AT CITY, COUNTY AND

点击翻译按钮获取中文摘要

Ceres Nanosciences, developer of Nanotrap particles for extracting and concentrating SARS-CoV-2, have successfully validated the use of these particles in multiple laboratories and contexts to capture and concentrate SARS-CoV-2 from biological solutions or wastewater at levels currently below the limit of detection of existing methods. This has attracted the interest of over 15 commercial partners, such as LabCorp, who are leading the national efforts to provide diagnostic tests for COVID-19 infection. The cumulative needs for these partners are tests in excess of 2,000,000/day. Our current manufacturing processes are not able to meet this demand and represent a bottleneck to helping to address the national crisis. As such, Ceres Nanosciences is requesting RADx support to rapidly scale-up Nanotrap manufacturing and distribution under our existing quality management system to meet the demand of partners, such as LabCorp, who are poised to leverage the technology for point-of-care and confirmatory testing for COVID-19 infection. EUA amendment data collection and supply contract agreements are in process.